The transitivity assumption, while statistically supported, is challenged by slight variation in baseline characteristics; SGLT2 inhibitor trials included a greater number of patients with heart failure and worse kidney function compared to GLP-1 receptor agonist trials. This evidence concerns the gene SLC5A2 and heart failure.